LONDON (Alliance News) - Life sciences company ValiRx PLC on Thursday said its VAL201 compound's Phase One and Two dose escalation clinical trial has been approved to include patients with locally-advanced or metastatic prostate cancer and other advanced solid tumours.
The trial to date has successfully demonstrated safety and tolerability, and there have been no significant adverse effects, ValiRx said. The trial will now advance to the dose escalation stage.
"The trial continues to proceed well, and I am pleased to be able to say that, at this preliminary stage, potential efficacy has been detected at the lowest doses. I look forward to making further updates in due course," said Satu Vainikka, ValiRx's chief executive.
Shares in ValiRx were up 0.4% to 58.25 pence on Thursday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
ValiRx (VAL)